메뉴 건너뛰기
.. 내서재 .. 알림
소속 기관/학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
로그인 회원가입 고객센터 ENG
주제분류

추천
검색
질문

논문 기본 정보

자료유형
학술저널
저자정보
Ram Hari Dahal (Kyungpook National University) Yoon-Jung Choi (Kyungpook National University) Shukho Kim (Kyungpook National University) Jungmin Kim (Kyungpook National University)
저널정보
대한미생물학회 JOURNAL OF BACTERIOLOGY AND VIROLOGY JOURNAL OF BACTERIOLOGY AND VIROLOGY Vol.54 No.2
발행연도
2024.6
수록면
107 - 121 (15page)

이용수

표지
📌
연구주제
📖
연구배경
🔬
연구방법
🏆
연구결과
AI에게 요청하기
추천
검색
질문

초록· 키워드

오류제보하기
Clostridioides difficile is a spore-forming enteric pathogen that causes life-threatening diarrhea and colitis. Notably, C. difficile infection (CDI) is a major healthcare-associated infection with increasing incidence and morbidity rates. Antibiotic-induced microbial disruption has been linked to susceptibility to CDI transmission and relapse. Therefore, alternative therapeutic approaches that effectively prevent C. difficile growth and spore germination are urgently needed. Bacteriophage-derived endolysins and their derivatives have recently shown potential as novel antibacterial agents. Hence, this study aimed to investigate the efficacy of a novel truncated cysteine-histidine-dependent amidohydrolase/peptidase (CHAP) modular endolysin, CHAP<SUP>SAP26</SUP>-161, in combating CDI. In vitro studies demonstrated its potent bactericidal activity against several clinically relevant C. difficile strains, including toxin A- and toxin B-producing and nontoxigenic strains. CHAP<SUP>SAP26</SUP>-161 exhibited rapid and specific killing activity, thereby significantly reducing C. difficile colony-forming units. Furthermore, in a murine CDI model, CHAP<SUP>SAP26</SUP>-161 treatment remarkably reduced C. difficile burden and clinical symptoms, such as diarrhea and weight loss. In histopathological analysis, colonic inflammation and tissue damage decreased in CHAPSAP26-161-treated mice compared with that in the control group. Moreover, no cytotoxic effects were observed on the A549 cell line, indicating that CHAP<SUP>SAP26</SUP>-161 is safe as a therapeutic agent. These findings highlight that CHAP<SUP>SAP26</SUP>-161 is a promising treatment option for CDI. Importantly, preclinical and clinical studies are warranted to fully evaluate the therapeutic potential of CHAPSAP26-161 and its possible implementation in clinical practice.

목차

INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
CONCLUSION
REFERENCES

참고문헌 (0)

참고문헌 신청

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!

최근 본 자료

전체보기

댓글(0)

0

UCI(KEPA) : I410-ECN-151-24-02-090106240